EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Socioeconomic‐ and Insurance‐Based Inequities in Oncotype DX Testing and Score‐Guided Treatment

Courtney P Williams iD, Jessica Shuey, Joud El Dick, Nusrat Jahan, Erica Stringer-Reasor, Andres Azuero, Gabrielle B Rocque iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.71485 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Courtney P Williams und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine & Population Science, University of Alabama at Birmingham, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Healthcare Disparities, Insurance Coverage, Insurance, Health. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Flatiron Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Personalized approaches to breast cancer treatment are increasingly guided by expensive, lab‐based genomic testing like Oncotype DX (ODX) Breast Recurrence Score Test. Little is known about how socioeconomic and insurance status may affect utilization of ODX testing and subsequent ODX score‐guided treatment.

Methods

This retrospective cohort study included women diagnosed with early‐stage, HR+/HER2‐ breast cancer from 2011 to 2023 within the US‐based, electronic health record (EHR)‐derived, deidentified Flatiron Health Research Database. Socioeconomic status was measured by a census block‐level measure of neighborhood deprivation. Insurance status was captured at the time of diagnosis. Utilization of ODX testing was compared descriptively. Age‐stratified likelihood of adjuvant chemotherapy by neighborhood deprivation or insurance status was estimated using relative risk, predicted probabilities, and 95% confidence intervals from adjusted Poisson models.

Results

Of 3814 patients eligible for ODX testing, 47% were commercially insured, and 31% lived in an impoverished neighborhood. Compared to those without, patients with an ODX test (47%, n = 1797) were more often white (81% vs. 74%), commercially insured (50% vs. 44%), or lived in an affluent neighborhood (72% vs. 66%). For patients aged ≤ 50 with low recurrence risk, patients who resided in affluent vs. impoverished neighborhoods had a 5% higher probability of receiving potentially inappropriate overtreatment with adjuvant chemotherapy. Of those with low/medium recurrence risk, publicly insured patients had more than double the probability of receiving adjuvant chemotherapy compared to those privately insured, suggesting potential overtreatment. For patients aged > 50 with ODX with high recurrence risk, Medicare beneficiaries had a 5% lower probability than privately insured patients and an 11% lower probability than Medicaid/Other beneficiaries of receiving recommended adjuvant chemotherapy, suggesting under treatment.

Conclusion

Socioeconomic‐ and insurance‐based inequities, including both overtreatment and undertreatment, were observed in this EHR‐based cohort of women with early‐stage breast cancer eligible for ODX testing, indicating opportunities to increase care quality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHealthcare DisparitiesInsurance CoverageInsurance, HealthHumansFemaleMiddle AgedRetrospective StudiesAgedAdultSocioeconomic FactorsChemotherapy, AdjuvantUnited StatesNeoplasm Recurrence, Local

Autor:innen und Institutionen

  • Division of General Internal Medicine & Population Science, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Division of Hematology & Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama, USA.

ORCID-Profile: Courtney P Williams, Gabrielle B Rocque

Förderung

  • Flatiron Health

Zitieren

APA

Williams, C. P., Shuey, J., El Dick, J., Jahan, N., Stringer-Reasor, E., Azuero, A., & Rocque, G. B. (2025). Socioeconomic‐ and Insurance‐Based Inequities in Oncotype DX Testing and Score‐Guided Treatment. Cancer Medicine. https://doi.org/10.1002/cam4.71485

Vancouver

Williams CP, Shuey J, El Dick J, Jahan N, Stringer-Reasor E, Azuero A, et al. Socioeconomic‐ and Insurance‐Based Inequities in Oncotype DX Testing and Score‐Guided Treatment. Cancer Medicine. 2025. doi:10.1002/cam4.71485

BibTeX
@article{Williams2025,
  author = {Williams, Courtney P and Shuey, Jessica and El Dick, Joud and Jahan, Nusrat and Stringer-Reasor, Erica and Azuero, Andres and Rocque, Gabrielle B},
  title = {Socioeconomic‐ and Insurance‐Based Inequities in Oncotype DX Testing and Score‐Guided Treatment},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71485}
}
Kostenlos starten →